ConductScience.org, home

Paper39475591

Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.

Ahn DH and 17 others. J Clin Oncol, 2025. Cited by 28 papers, by iCite.

Cite this record

ConductScience Library. Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. Papers, record 39475591. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39475591

Download JSON
Disease
colorectal cancer741 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.
PubMed
Journal
J Clin Oncol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Clinical Trial, Phase II, Multicenter Study, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
28
iCite
Relative citation ratio, by iCite
6.22, provisional
iCite
Revised in PubMed
2026-06-02
PubMed

Authors18

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ahn DHDaniel Hhttps://orcid.org/0000-0002-0161-4018
2Ridinger MMayahttps://orcid.org/0000-0001-5833-5573
3Cannon TLTimothy Lhttps://orcid.org/0000-0001-5033-3071
4Mendelsohn LLawrence
5Starr JSJason Shttps://orcid.org/0000-0003-4922-1392
6Hubbard JMJoleen Mhttps://orcid.org/0000-0001-8250-4920
7Kasi AAnuphttps://orcid.org/0000-0002-4305-5701
8Barzi AAfsanehhttps://orcid.org/0000-0002-0032-2988
9Samuëlsz EErrinhttps://orcid.org/0000-0002-3424-7330
10Karki AAnjuhttps://orcid.org/0000-0003-4042-0045
11Subramanian RARamanand Ahttps://orcid.org/0009-0005-2741-2675
12Yemane DDivora
13Kim RRoy
14Wu CCChu-Chiaohttps://orcid.org/0009-0007-5198-7668
15Croucher PJPPeter J Phttps://orcid.org/0000-0003-1437-0224
16Smeal TTod
17Kabbinavar FFFairooz F
18Lenz HJHeinz-Josefhttps://orcid.org/0000-0003-2178-9568

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Colorectal NeoplasmsMajor topic
Proto-Oncogene Proteins p21(ras)Major topic
Humans
Bevacizumab
Male
Female
Middle Aged
Aged
Adult
Mutation
Leucovorin
Fluorouracil
Camptothecin
Progression-Free Survival
Aged, 80 and over

Source PubMed

Download CSV of topics

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT03829410Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS MutationResultsYesClinicalTrials.gov
NCT06106308
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Derived from the trialYesClinicalTrials.gov

Download CSV of trials

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in39561313Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.https://conductscience.org/library/papers/39561313

Source PubMed

Download CSV of comments and corrections

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134244683Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment.Nat Rev Cancer2021https://conductscience.org/library/papers/34244683PubMed
227240256Data-driven hypothesis weighting increases detection power in genome-scale multiple testing.Nat Methods2016https://conductscience.org/library/papers/27240256PubMed
337992175HILPS, a long noncoding RNA essential for global oxygen sensing in humans.Sci Adv2023https://conductscience.org/library/papers/37992175PubMed
424143206The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer.PLoS One2013https://conductscience.org/library/papers/24143206PubMed
526771021The Molecular Signatures Database (MSigDB) hallmark gene set collection.Cell Syst2015https://conductscience.org/library/papers/26771021PubMed
632175278Resistance Mechanisms to Anti-angiogenic Therapies in Cancer.Front Oncol2020https://conductscience.org/library/papers/32175278PubMed
738231047Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.Clin Cancer Res2024https://conductscience.org/library/papers/38231047PubMed
835167329First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1).J Clin Oncol2022https://conductscience.org/library/papers/35167329PubMed
927358379
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group.
Ann Oncol2016https://conductscience.org/library/papers/27358379PubMed
1037460927Novel cancer treatment paradigm targeting hypoxia-induced factor in conjunction with current therapies to overcome resistance.J Exp Clin Cancer Res2023https://conductscience.org/library/papers/37460927PubMed
1123828442KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials.Med Oncol2013https://conductscience.org/library/papers/23828442PubMed
1236546659Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.N Engl J Med2023https://conductscience.org/library/papers/36546659PubMed
1334919824Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial.Lancet Oncol2022https://conductscience.org/library/papers/34919824PubMed
1415175435Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.N Engl J Med2004https://conductscience.org/library/papers/15175435PubMed
1517442997
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.
J Clin Oncol2007https://conductscience.org/library/papers/17442997PubMed
1622319201NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.Mol Cancer Ther2012https://conductscience.org/library/papers/22319201PubMed
1732955176KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.N Engl J Med2020https://conductscience.org/library/papers/32955176PubMed
1831727675Impact of Prior Bevacizumab Treatment on VEGF-A and PlGF Levels and Outcome Following Second-Line Aflibercept Treatment: Biomarker Post Hoc Analysis of the VELOUR Trial.Clin Cancer Res2020https://conductscience.org/library/papers/31727675PubMed
1938587856Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.Cancer Discov2024https://conductscience.org/library/papers/38587856PubMed
2019224847Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.J Clin Oncol2009https://conductscience.org/library/papers/19224847PubMed

See all 39 referencesDownload CSV of references

Cited by25

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.

PMIDTitleJournalYearIn PapersSource
42947311Targeting G2/M checkpoint vulnerability in homologous recombination-proficient tumors: lessons from ovarian cancer models.Cell Cycle2026https://conductscience.org/library/papers/42947311PubMed
42907995Astragali Radix-Curcumae Rhizoma synergistically potentiates 5-fluorouracil antitumor efficacy in colorectal cancer by disrupting DNA repair-cell cycle coordination.Chin Med2026https://conductscience.org/library/papers/42907995PubMed
42782861KRAS in Colorectal Cancer: Tumorigenesis, Surgical Implications and Evolving Treatment Target.Curr Oncol2026https://conductscience.org/library/papers/42782861PubMed
42778539Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.Signal Transduct Target Ther2026https://conductscience.org/library/papers/42778539PubMed
42510676Immune-Metabolic Profiling Reveals Functional Heterogeneity Within Colorectal Cancer Consensus Molecular Subtypes.Biology (Basel)2026https://conductscience.org/library/papers/42510676PubMed
42443409PLK1 inhibition enhances Brentuximab vedotin efficacy in CD30-positive T-cell lymphoma via spindle assembly checkpoint activation.Leukemia2026https://conductscience.org/library/papers/42443409PubMed
42380087α-ketoglutarate accumulation orchestrates immunosuppressive metabolic remodeling to drive cetuximab resistance in metastatic colorectal cancer.Cell Death Dis2026https://conductscience.org/library/papers/42380087PubMed
42376209PLK1: A Promising Therapeutic Target for Prostate Cancer Treatment.Serican J Med2024https://conductscience.org/library/papers/42376209PubMed
42194957Clinical Applications of Liquid Biopsy in Colorectal Cancer: A Focus on Registered Clinical Trials.Genes (Basel)2026https://conductscience.org/library/papers/42194957PubMed
41782869Mass spectrometry-based multi-omics analysis elucidates immune microenvironmental characteristics and the risk of distant metastasis in N1c colorectal cancer.Front Immunol2026https://conductscience.org/library/papers/41782869PubMed
41523245Targeted therapy for KRAS G12C-mutated colorectal cancer: advances, challenges, and future directions.Am J Cancer Res2025https://conductscience.org/library/papers/41523245PubMed
41458961Clinical relevance of PLK1 in epithelial ovarian cancer.Front Pharmacol2025https://conductscience.org/library/papers/41458961PubMed
41354716PLK1 or WEE1 inhibition targets homologous recombination repair proficiency in BRCA1/2 wild-type high-grade serous ovarian cancer.Cell Death Dis2025https://conductscience.org/library/papers/41354716PubMed
41045302PLK1 inhibition enhances gemcitabine-induced apoptosis through PLK1-dependent ERK1/2-Bim and AKT1/Noxa signals in pancreatic cancer cells.Med Oncol2025https://conductscience.org/library/papers/41045302PubMed
41018484Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer.Explor Target Antitumor Ther2025https://conductscience.org/library/papers/41018484PubMed
40935881Synthetic lethality in cancer drug discovery: challenges and opportunities.Nat Rev Drug Discov2026https://conductscience.org/library/papers/40935881PubMed
40615690Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancer.Oncogene2025https://conductscience.org/library/papers/40615690PubMed
40565172Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas.Int J Mol Sci2025https://conductscience.org/library/papers/40565172PubMed
40496862Integrative genomic and single-cell framework identifies druggable targets for colorectal cancer precision therapy.Front Immunol2025https://conductscience.org/library/papers/40496862PubMed
40412794Polo-like kinase 1 inactivation enhances PI3K inhibition-mediated apoptosis of NOTCH1-mutant head and neck squamous cell carcinoma.Cancer Lett2025https://conductscience.org/library/papers/40412794PubMed

See all 25 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
KRAS3845PubTator's text mininghttps://conductscience.org/library/genes/3845NCBI Gene
PLK15347PubTator's text mininghttps://conductscience.org/library/genes/5347NCBI Gene

Download CSV of genes

Drugs6

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
BEVACIZUMABCHEMBL1201583Results2https://conductscience.org/library/drugs/CHEMBL1201583ChEMBL
LEUCOVORINCHEMBL1679Results2https://conductscience.org/library/drugs/CHEMBL1679ChEMBL
ONVANSERTIBCHEMBL1738758Results2https://conductscience.org/library/drugs/CHEMBL1738758ChEMBL
FLUOROURACILCHEMBL185Results2https://conductscience.org/library/drugs/CHEMBL185ChEMBL
OXALIPLATINCHEMBL414804Derived from the trial1https://conductscience.org/library/drugs/CHEMBL414804ChEMBL
IRINOTECANCHEMBL481Results2https://conductscience.org/library/drugs/CHEMBL481ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39475591

GET https://conductscience.org/api/papers/v1/39475591/references?page=2